2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol | 2121514-67-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
• CAS: 2121514-67-6
• 化学式: C₁₂H₁₆BFO₃
• 分子量: 238.067
• InChiKey: YMBJGACWPPFGDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.83
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium carbonate 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 生成
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES COMME IMMUNOMODULATEURS D'INTERACTIONS DE PD-L1

  摘要：

  PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor compounds singly or in combination with additional agents and compositions of such PD-L1 inhibitor compounds for the treatment of cancer and other conditions are disclosed.

  公开号：

  WO2023272720A1
• 作为产物：
  描述：

  3-溴-2-氟苯酚 、 联硼酸频那醇酯 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 生成 2-fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS OF PD-L1 INTERACTIONS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES UTILES COMME IMMUNOMODULATEURS D'INTERACTIONS DE PD-L1

  摘要：

  PD-L1 inhibitors of various compound formulas, both generically and specifically are disclosed. Methods of making such PD-L1 inhibitor compounds are disclosed, both generically and specifically. Methods of using such PD-L1 inhibitor compounds singly or in combination with additional agents and compositions of such PD-L1 inhibitor compounds for the treatment of cancer and other conditions are disclosed.

  公开号：

  WO2023272720A1

文献信息

• [EN] METHODS AND COMPOSITIONS FOR TARGETING PD-L1<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR LE CIBLAGE DE PD-L1
  申请人：ALIGOS THERAPEUTICS INC

  公开号：WO2021236771A1

  公开（公告）日：2021-11-25

  The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and uses of or methods of using a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for the treatment of PD-L1 related diseases including but not limited to liver diseases, cancer, hepatocellular carcinoma, viral diseases, or hepatitis B.

  本公开涉及可用作PD-1、PD-L1或PD-1/PD-L1相互作用抑制剂的化合物。本公开还涉及可以包括式(I)化合物或其药学上可接受的盐的药物组合物，以及使用式(I)化合物或其药学上可接受的盐治疗PD-L1相关疾病的用途或方法，包括但不限于肝病、癌症、肝细胞癌、病毒性疾病或乙型肝炎。
• Para-Selective, Iridium-Catalyzed C–H Borylations of Sulfated Phenols, Benzyl Alcohols, and Anilines Directed by Ion-Pair Electrostatic Interactions
  作者：Jose R. Montero Bastidas、Thomas J. Oleskey、Susanne L. Miller、Milton R. Smith、Robert E. Maleczka

  DOI：10.1021/jacs.9b08464

  日期：2019.10.2

  Para C-H borylation (CHB) of tetraalkylammonium sulfates and sulfamates have been achieved using bipyridne-ligated Ir boryl catalysts. Selectivities can be modulated both by the length of the alkyl groups in the tetraalkylammonium cations and the substituents on the bipyridine ligands. Ion-pairing, where the alkyl groups of the cation shield the meta C-H bonds in the conteranions, is proposed to account

  四烷基硫酸铵和氨基磺酸盐的对位 CH 硼化 (CHB) 已使用联吡啶连接的 Ir boryl 催化剂实现。选择性可以通过四烷基铵阳离子中烷基的长度和联吡啶配体上的取代基来调节。离子对，其中阳离子的烷基屏蔽了对位离子中的间位 CH 键，被认为是对位选择性的原因。4,4'-二甲氧基-2,2'-联吡啶配体具有优异的选择性。
• [EN] HETEROCYCLIC PAD4 INHIBITORS<br/>[FR] INHIBITEURS DE PAD4 HÉTÉROCYCLIQUES
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021163254A1

  公开（公告）日：2021-08-19

  The disclosure generally relates to substituted heterocyclic compounds of Formula (Ia), which are inhibitors of PAD4, method for preparing these compounds, pharmaceutical compositions comprising these compounds and use of these compounds in the treatment of a disease or a disorder associated with PAD4 enzyme activity.

  该披露通常涉及Formula (Ia)的取代杂环化合物，这些化合物是PAD4的抑制剂，制备这些化合物的方法，包含这些化合物的药物组合物以及使用这些化合物治疗与PAD4酶活性相关的疾病或障碍的方法。